Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | IL2 | P60568 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.85 |
| ▸ | KDM1A | O60341 | 3/20 | 0.81 |
| ▸ | XDH | P47989 | 3/20 | 0.78 |
| ▸ | KDM4A | O75164 | 1/20 | 0.75 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galuteolin SCHEMBL30282117 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL242535 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL19523005 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL2126750 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL16755609 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL17232556 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL149118 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL4984197 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL22510086 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL29374275 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131558-A | Multifunctional particles for aquatic product cultivation and processing and preparation method thereof | 浙江海洋大学 | 2025-06-13 | — | — | CN | claimed |
| CN-120053656-A | Medicine target spot of cynaroside C for resisting ciliate, application and medicine for killing ciliate | 暨南大学 | 2025-05-30 | — | — | CN | claimed |
| CN-113881602-B | High-yield C 21 Steroid bacillus cereus X-32 and application thereof | 盐城师范学院 | 2024-02-06 | — | — | CN | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| CN-113817614-B | High-efficiency synthesis C 21 Alternaria alternata Z-44 of steroid glycoside and application thereof | 盐城师范学院 | 2023-06-27 | — | — | CN | claimed |
| CN-114150053-A | Combination factor and application thereof | 重庆美普蓝科技有限公司 | 2022-03-08 | — | — | CN | claimed |
| US-11229204-B2 | Herbicidal composition comprising at least one phenolic active compound | Université de Liège (BE) | 2022-01-25 | — | — | US | claimed |
| WO-2021194436-A1 | THE NATURAL ANTIVIRAL AND ANTI-INFLAMMATORY COMPOUND CONSIST OF BIOFLAVONOIDS WHICH EXTRACTED FROM PAPAVER RHOEAS RED PETALS | NANOBIOMED SAĞLIK VE YAŞAM BILIMLERI A. Ş. (TR) | 2021-09-30 | — | — | WO | claimed |
| CN-112237590-A | Chenopodium formosanum juice, its application and fat reducing composition | 百岳特生物技术（上海）有限公司 | 2021-01-19 | — | — | CN | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2013-01-24 | — | — | US | claimed |
| EP-2523946-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | InterMed Discovery GmbH (DE) | 2012-11-21 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| WO-2011085979-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2011-07-21 | — | — | WO | claimed |
| EP-2345646-A1 | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions | InterMed Discovery GmbH (DE) | 2011-07-20 | — | — | EP | claimed |
| WO-2010130685-A1 | EXTRACT OF AERIAL PARTS OF ARTICHOKE AND METHOD OF PRODUCTION | BIOFARMITALIA S.P.A. (IT) | 2010-11-18 | — | — | WO | claimed |
| US-20090232913-A1 | Composition for the Control of Cholesterol Levels | VANADIS BIOSCIENCE LTD. (NZ) | 2009-09-17 | — | — | US | claimed |
| US-20090074895-A1 | COMPOSITION AND USES THEREOF | VANADIS BIOSCIENCE LTD (NZ) | 2009-03-19 | — | — | US | claimed |
| WO-2006116814-A1 | COMPOSITION AND USES THEREOF | VANADIS BIOSCIENCE LTD (NZ) | 2006-11-09 | — | — | WO | claimed |
| WO-2006116815-A1 | COMPOSITION FOR THE CONTROL OF CHOLESTEROL LEVELS | VANADIS BIOSCIENCE LTD (NZ) | 2006-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232913-A1 | Composition for the Control of Cholesterol Levels | CETP, HMGCR, CYP46A1 | MEN1 1235/4885KMT2A 2372/4885KDM4E 4093/4885 |
| US-20090074895-A1 | COMPOSITION AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | MEN1 1417/4885KMT2A 3488/4885KDM4E 4309/4885 |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | CETP, LIPC, FABP4 | MEN1 3533/4885KMT2A 1784/4885KDM4E 2816/4885 |
| US-11229204-B2 | Herbicidal composition comprising at least one phenolic active compound | DDT, DNPH1, KEAP1 | MEN1 2489/4885KMT2A 436/4885KDM4E 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.